Datopotamab-deruxtecan

Datopotamab deruxtecan (Dato-DXd, DS-1062)

一行要約

Datopotamab deruxtecan (Dato-DXd, DS-1062) は TROP2 標的 ADCで、Daiichi Sankyo / AstraZeneca 共同開発の deruxtecan platform (T-DXd と同 payload) を使用。Humanized anti-TROP2 IgG1 抗体 + cleavable tetrapeptide linker + DXd (exatecan derivative, topoisomerase I inhibitor) で構成、DAR 約4。NSCLC 領域では TROPION-Lung01 (vs docetaxel 2L+) で PFS benefit、TROPION-Lung08 (1L with pembrolizumab) で IO + ADC combination 評価、HR+ breast でも TROPION-Breast01 で OS benefit。Sacituzumab govitecan に続く TROP2 ADC 第二世代として臨床開発が急速に進む。

主要試験

• TROPION-Lung01 (Ahn 2025 JCO): 2L+ NSCLC で Dato-DXd vs docetaxel, PFS benefit (HR 0.75, p=0.004), ORR 26.4%、特に non-squamous で improvement、squamous では benefit なし。EGFR mutant subgroup で benefit pronounced → 2025-06 FDA accelerated approval (EGFR mutant NSCLC, 2L+)
• ICARUS-LUNG01 (Planchard et al. CancerCell 2026): 前治療 NSCLC 100 例 phase 2、ORR 26.0% / mPFS 3.6 mo / mOS 11.9 mo で TROPION-Lung01 と再現性確認。EGFR/BRAFV600E 群 ORR 50%、KRAS 群 ORR 63.6% と driver-positive subgroup での enrichment を示した
• TROPION-Lung02 / Lung04: 1L NSCLC with pembrolizumab ± platinum, ORR 50-60% with manageable safety
• TROPION-Lung08: 1L PD-L1 high NSCLC で Dato-DXd + pembrolizumab vs pembrolizumab, primary endpoint データ pending
• TROPION-Lung12: peri-operative 設定 (with durvalumab)
• TROPION-Breast01: HR+ HER2− breast 2L+ で Dato-DXd vs CT-of-physician’s-choice, OS benefit (Bardia 2024 JCO)
• TROPION-PanTumor01: pan-tumor basket (esophageal, gastric, urothelial, ovarian)

Translational biomarker insights (ICARUS-LUNG01)

ICARUS-LUNG01 が Dato-DXd 応答機序の縦断的解析を初めて系統化:

1. TROP2 cytoplasmic distribution: 単純な membrane H-score では応答予測に不十分。cytoplasmic 染色 variance が低い (= より uniform な internalization) ほど responder に enrich (p=0.003)。TROPION-Lung01 探索的解析の QCS-NMR (normalized membrane ratio) と方向性一致 — 単一 IHC cut-off ではなく endocytosis dynamics の定量が next-gen biomarker
2. SLFN11 の感受性決定: BL/on-T で SLFN11+ tumor cell proportion が responder で一貫して高く (BL median 8.4 vs 2.4, C1D3 13.4 vs 3.0)、CRISPR KO で Dato-DXd 感受性が 10-50 倍低下 — DDR 阻害剤 (PARP/ATR/WEE1) との rational combination の理論的根拠
3. DNA repair pathway 活性化が抵抗性に寄与: bulk RNA-seq で non-responder 中心に RAD51 pathway 活性化 (adj p<0.05) → 治療誘導性 DDR adaptation
4. Adaptive anti-tumor immune response: responder で on-T に CD8+GzmB+ T 細胞増加 + IFNα 応答 上昇 (NES=1.69, adj p=0.01) — cGAS-STING 経由の immunogenic effect が PD-(L)1 併用の根拠を補強。HER3-DXd (patritumab deruxtecan) でも同方向性が報告されている

メカニズム

(1) IgG1 anti-TROP2 が tumor cell 表面 TROP2 を結合 → clathrin-mediated endocytosis。(2) lysosomal protease (cathepsin L 等) が tetrapeptide linker (Gly-Gly-Phe-Gly) を切断 → DXd payload 放出。(3) DXd は exatecan derivative で topoisomerase I 阻害 → DNA single-strand break → S-phase replication fork collapse → apoptosis。(4) DXd は membrane-permeable で tumor cell 死後に隣接 tumor cell (low TROP2) にも diffuse → bystander effect で heterogeneity 克服。

T-DXd (HER2 ADC) と同 payload・同 linker (deruxtecan platform) で抗体のみ TROP2 標的に変更。耐性機序は TROP2 down-regulation, lineage plasticity (NE / squamous transformation), DXd efflux pump (ABCG2), DDR alteration。

臨床位置づけ

Approved: EGFR mutant NSCLC 2L+ (FDA accelerated 2025-06、TROPION-Lung01 EGFR subgroup の benefit ベース)。Driver-negative / non-squamous NSCLC 2L+ は docetaxel (旧 standard) を上回る PFS benefit があり、squamous では benefit なし (histology-driven pattern)。1L 設定 (TROPION-Lung08) は PD-1 + ADC combination の foundational trial で、IO 既存 standard を上回るかが question。

ADC sequencing (post-EGFR-TKI): Osimertinib 後の choices として Dato-DXd (TROP2) / Patritumab deruxtecan (HER3-DXd) / Trastuzumab deruxtecan (HER2 共発現群) / Telisotuzumab vedotin (MET amp) の 4 系列 ADC が並列。直接比較 RCT は不在で、driver subset (EGFR mutant 全般 → Dato-DXd / HER3-DXd; HER2 mutation/co-amp → T-DXd; MET amp → Teliso-V) に応じた使い分けが現状の rule of thumb。同 platform (deruxtecan) 系列の cross-resistance が懸念されるが、target が異なれば response は独立しうる — ICARUS-LUNG01 が示した SLFN11 / DDR / cytoplasmic TROP2 の predictive 軸が共通 biomarker framework となりうる。詳細は egfr-osimertinib-post-resistance-strategy / adc-payload-diversity-ild-management 参照。

Adverse event: ILD (約5-10%, deruxtecan platform 共通の severe AE; ICARUS-LUNG01 では adjudicated drug-related ILD が独立委員会判定で grade 1 1 例のみ), oral mucositis 48% / nausea 47% / alopecia 41% / fatigue 33%。ILD prevention / monitoring protocol が clinical practice の central concern。Predictive biomarker は TROP2 IHC NMR (membrane normalized ratio) / cytoplasmic variance / SLFN11 expression / c-DAR が探索段階で、TROPION-Lung14 (NCT06350097) / Lung15 (NCT06417814) で複合バイオマーカー validation が進行中。

Open Questions

• TROP2 IHC predictive value: NMR / c-DAR の prospective validation
• ILD prevention / management standardization
• ADC + IO sequencing: 1L Dato-DXd + pembrolizumab vs 1L pembrolizumab → 2L ADC の比較
• Brain metastasis activity: ADC の CNS efficacy data
• ADC 連続使用 / cross-resistance: TROP2 ADC → HER3 ADC / HER2 ADC の sequencing
• Squamous NSCLC での efficacy (TROPION-Lung01 で nonsquamous benefit pronounced)

関連エンティティ

• 関連薬剤: ADC / HER2-directed-therapy / HER3-directed-therapy / PD-1-inhibitor / Pembrolizumab / Docetaxel / Platinum-chemotherapy
• 関連遺伝子: TROP2 / HER2 / CDH1
• 関連経路: DDR-pathway / Apoptosis-pathway
• 関連概念: ADC-resistance-mechanisms / Lineage-plasticity / EMT / IO-primary-resistance / Brain-metastasis-immune-microenvironment

関連論文

Basic-Oncogene and genetics

• Liao et al. CancerCell 2026 — Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell

Clinical-NSCLC-Driver negative

• Kato et al. JImmunotherCancer 2020 — Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with

Clinical-NSCLC-Driver-Other

• Inamura et al. Oncotarget 2017 — Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes

Clinical-NSCLC-EGFR

• Piotrowska et al. CancerDiscov 2026 — ELIOS A multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated
• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following
• Zhao et al. NatRevClinOncol 2026 — Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC-mechanisms and evolving treatment approaches

Clinical-Novel modalities

• Garrido-Castro et al. AnnOncol 2026 — SACI-IO HR+ A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with
• Planchard et al. CancerCell 2026 — Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer ICARUS-LUNG01
• Chen et al. FrontOncol 2026 — Evolution and recent advances in antibody-drug conjugate therapy for lung cancer a comprehensive systematic review
• Hofman et al. LungCancer 2026 — New biomarkers for antibody-drug conjugates in lung cancer the pathologist’s perspective
• Li et al. MolCancer 2026 — Antibody-drug conjugates in breast cancer from mechanism to revolutionizing clinical practice

合成 (Outputs)

• novel-modality-sequencing-driver-resistance